Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProHer home versus hospital administration preference study
PACTR202211579014330Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of pertuzumab and trastuzumab in breast cancer (4 arms), sponsored by Roche. Primary endpoint: Percentage of participants who preferred home administration of PH FDC SC compared with hospital administration. Started Jul 2022; status: recruiting.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202211579014330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202211579014330.